Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PPIA | P62937 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30510414 | 1.00 | PPARG (0.33) | PPARGMEN1KMT2APPIACYP2D6 | |
| SCHEMBL30510418 | 0.90 | PPIA (0.37) | PPARGKMT2APPIACYP2D6SLC6A2 | |
| SCHEMBL25179592 | 0.88 | PPIA (0.31) | PPARGPPIACYP2D6SLC6A2SLC6A4 | |
| SCHEMBL27215385 | 0.86 | PPIA (0.41) | PPARGMEN1KMT2APPIACYP2D6 | |
| SCHEMBL25186515 | 0.86 | PPIA (0.41) | PPARGMEN1KMT2APPIACYP2D6 | |
| SCHEMBL30510307 | 0.83 | ALDH1A1 (0.35) | MEN1KMT2APPIACYP1A2TSHR | |
| SCHEMBL27078253 | 0.83 | ALDH1A1 (0.35) | MEN1KMT2APPIACYP1A2TSHR | |
| SCHEMBL25179578 | 0.83 | PPARG (0.39) | PPARGKMT2ACYP2D6SLC6A2SLC6A4 | |
| SCHEMBL30767804 | 0.83 | PPARG (0.39) | PPARGKMT2ACYP2D6SLC6A2SLC6A4 | |
| SCHEMBL15240994 | 0.82 | CTNNB1 (0.41) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | PPARG 3626/4885MEN1 158/4885KMT2A 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.